MSD Germany has appointed Dr Susanne Fiedler as CEO to take over from Hanspeter Quodt, who steps after seven years in the post.
Dr Fielder first joined the German operations of Merck & Co in 1997, when she took up a role in market research.
She then moved to market, initially as a product manager and later as a marketing manager and then a business unit head with responsibility for a number of MSD products.
Since then Dr Fielder has served in the US, where MSD operates at Merck & Co, as global brand leader for the diabetes treatments Januvia and Janumet, before taking up a Sydney-based role as managing director of MSD Australia and New Zealand.
She will officially take on her new role on 1 February, when Quodt moves to a new European level position.
Source: PMLive
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.